Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
ADVIL (Ibuprofen Sodium) is an oral tablet nonsteroidal anti-inflammatory drug (NSAID) indicated for pain relief and fever reduction. It is a small-molecule analgesic/anti-inflammatory agent that inhibits prostaglandin synthesis. Ibuprofen sodium is the faster-acting salt formulation of ibuprofen, designed for rapid onset of action.
Peak lifecycle indicates mature, stable market with established sales infrastructure; brand management focus shifts toward defensive positioning and market share retention rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects
Ibuprofen Sodium Tension Headache Study
Bioequivalence of a Fixed Dose Combination Tablet Containing 200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl Compared to RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) as a Fixed Dose Combination Tablet Administered in Healthy Volunteers.
Worked on ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ADVIL offers career exposure in mature brand management, defensive market positioning, and OTC commercial strategy within a stable, predictable revenue environment. Opportunities emphasize commercial execution, consumer marketing, and operational efficiency over clinical innovation or launch dynamics.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo